ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021
A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07583992 (Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia), which is not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia
Who cites it
58 citing papers in PubMed, 106 citations in OpenAlex.
- A Houttuynia cordata-based Chinese herbal formula improved symptoms of allergic rhinitis during the COVID-19 pandemic.Journal of the Chinese Medical Association : JCMA · 2022Trial
- Renoprotective Effects of a Herbal Formulation Against Lipopolysaccharide-Induced Acute Kidney Injury Through Anti-Inflammatory and Antioxidant Activities.Life (Basel, Switzerland) · 2026Article
- Association Between Prior NRICM101 Use and Response to Incentive Spirometer Training in Patients with Long COVID.Healthcare (Basel, Switzerland) · 2026Article
- Chemical characterization of Jing Guan Fang and its application in alleviating coronavirus envelope protein-induced proinflammatory responsesJournal of traditional and complementary medicine · 2026Article
- NRICM102, a TCM Formula, Attenuates COPD-Relevant Inflammatory Lung Injury in Mice by Improving Pulmonary Function and Reversing Immune Dysregulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Effects of incentive spirometer training on dyspnea and functional status in patients with long COVID.PloS one · 2026Article
- Evaluating the antiviral efficacy and specificity of chlorogenic acid and related herbal extracts against SARS-CoV-2 variants via spike protein binding intervention.Journal of traditional and complementary medicine · 2025Article
- Oral Administration of Trichosanthes Kirilowii Fruit Extract Ameliorates Airway Inflammation and Suppresses Th2 Cell Activities in Ovalbumin-Sensitized Mice.The Kaohsiung journal of medical sciences · 2025Article
- Screening of Medicinal Herbs IdentifiesViruses · 2025Article
- Association of Psychosocial and Health Factors with Long COVID Symptoms in Students in Medicine-Related Departments: A Cross-Sectional Survey.Healthcare (Basel, Switzerland) · 2025Article
- Taiwan Chingguan Yihau may improve post-COVID-19 respiratory complications through PI3K/AKT, HIF-1, and TNF signaling pathways revealed by network pharmacology analysis.Molecular diversity · 2025Article
- A pre- and post-course survey of an elective Chinese medicine curriculum among junior Western medical students in Taiwan.BMC complementary medicine and therapies · 2025Article
- Toxicological assessment of novel Anti-COVID traditional Chinese medicine formulae NRICM101 and NRICM102: a comprehensive study on safety and genotoxicity.Frontiers in pharmacology · 2025Article
- Ethnobotanical survey of herbal medicines for anti-COVID-19 used by traditional Chinese medicine pharmacies in Taiwan.Frontiers in pharmacology · 2025Article
- Article
- NRICM101 in combatting COVID-19 induced brain fog: Neuroprotective effects and neurovascular integrity preservation in hACE2 mice.Journal of traditional and complementary medicine · 2025Article
- Impact of the Coronavirus Disease 2019 [COVID-19] Pandemic on Post-Acute Care of Patients with Heart Failure and the Effectiveness of Vaccine Prevention.Healthcare (Basel, Switzerland) · 2024Article
- Clinical presentations, systemic inflammation response and ANDC scores in hospitalized patients with COVID-19.Scientific reports · 2024Observational
- The anti-COVID-19 drug nirmatrelvir crosses the blood‒brain barrier and exhibits herb-drug pharmacokinetic interactions withHeliyon · 2024Article
- The Bioactive Compounds ofPharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020. Its clinical outcomes and pharmacology have been evaluated. Among 33 patients with confirmed COVID-19 admitted in two medical centers, those (n = 12) who were older, sicker, with more co-existing conditions and showing no improvement after 21 days of hospitalization were given NRICM101. They achieved 3 consecutive negative results within a median of 9 days and reported no adverse events. Pharmacological assays demonstrated the effects of the formula in inhibiting the spike protein/ACE2 interaction, 3CL protease activity, viral plaque formation, and production of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α. This bedside-to-bench study suggests that NRICM101 may disrupt disease progression through its antiviral and anti-inflammatory properties, offering promise as a multi-target agent for the prevention and treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.